Valuation: CorMedix Inc.

Market Cap 612M 537M 507M 462M 865M 58.63B 871M 6.07B 2.35B 29.93B 2.3B 2.25B 96.18B P/E 2026 *
15.9x
P/E 2027 * 139x
Enterprise Value 502M 441M 416M 379M 711M 48.14B 715M 4.98B 1.93B 24.58B 1.89B 1.85B 78.98B EV / Sales 2026 *
1.49x
EV / Sales 2027 * 1.61x
Free-Float
92.39%
Yield 2026 *
-
Yield 2027 * -
1 day+1.03%
1 week+1.68%
Current month-4.96%
1 month-8.29%
3 months+1.68%
6 months+18.76%
Current year-32.50%
1 week 7.62
Extreme 7.62
8.18
1 month 7.62
Extreme 7.62
8.74
Current year 6.12
Extreme 6.125
12.29
1 year 6.12
Extreme 6.125
13.02
3 years 2.57
Extreme 2.57
17.43
5 years 2.57
Extreme 2.57
17.43
10 years 0.86
Extreme 0.8605
18.8
Manager TitleAgeSince
Chief Executive Officer 50 09/05/2022
Director of Finance/CFO 54 28/08/2025
Compliance Officer 66 11/12/2023
Director TitleAgeSince
Director/Board Member 67 05/08/2015
Chairman 81 02/08/2017
Director/Board Member 70 15/08/2011
Date Insider Type Main position Quantity % Market Cap. Importance
18/09/26 Exercice

Director

97,818 0.1255%
29/08/26 Tax

Chief Financial Officer

-8,424 0.0108%
29/08/26 Tax

Compliance Officer

-8,424 0.0108%
Change 5-day change 1-year change 3-year change Capi.($)
+1.03%+1.68%-29.41%+112.74% 612M
+0.54%+1.30%+91.73%+40.57% 367B
+0.78%+3.97%+27.12%-14.58% 66.89B
-1.15%+1.29%+53.98%+192.88% 12.93B
+0.24%+0.49%-1.88%-16.04% 7.54B
-1.30%-2.32%-27.85%-11.12% 4.38B
-1.33%-2.37%-37.20%+5.00% 4.07B
-4.23%+2.14%-30.63%-11.67% 3.02B
-1.46%+1.57%-9.58%+49.37% 2.48B
-2.18%-0.66%-22.30%-33.51% 1.91B
Average -0.91%+0.13%+1.40%+31.36% 47.09B
Weighted average by Cap. +0.44%+1.56%+75.85%+34.73%

Financials

2026 *2027 *
Net sales 337M 296M 279M 254M 477M 32.3B 480M 3.34B 1.29B 16.49B 1.27B 1.24B 52.98B 289M 254M 240M 218M 409M 27.72B 412M 2.87B 1.11B 14.15B 1.09B 1.06B 45.47B
Net income 45.67M 40.09M 37.83M 34.47M 64.58M 4.38B 65.03M 453M 175M 2.23B 171M 168M 7.18B 5.33M 4.68M 4.41M 4.02M 7.54M 511M 7.59M 52.84M 20.43M 261M 20.01M 19.57M 838M
Net Debt -109M -96.07M -90.63M -82.59M -155M -10.48B -156M -1.08B -420M -5.35B -411M -402M -17.2B -147M -129M -122M -111M -208M -14.12B -210M -1.46B -565M -7.21B -553M -541M -23.16B
Logo CorMedix Inc.
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
Employees
191
Date Price Change Volume
25/09/26 US$7.850 +1.03% 606,652
24/09/26 US$7.770 +1.04% 946,580
23/09/26 US$7.690 -1.16% 812,571
22/09/26 US$7.780 +0.13% 788,926
21/09/26 US$7.770 +0.65% 505,842
Trader
Investor
Global
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
7.850USD
Average target price
15.33USD
Spread / Average Target
+95.33%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CRMD Stock